The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The blood screening market plays a vital role in ensuring the safety of blood transfusions and early detection of infectious diseases. It involves the testing of donated blood for a variety of transmissible pathogens such as HIV, hepatitis B and C, syphilis, and other infections that pose significant health risks. With rising global awareness around blood safety and the increasing demand for reliable diagnostic solutions, the market is witnessing steady growth. Advancements in screening technologies, including nucleic acid testing and immunoassays, have enhanced the accuracy and speed of detection, making blood screening more efficient and accessible. The market is also being driven by the growing number of blood donations, expanding healthcare infrastructure in emerging economies, and government initiatives promoting voluntary blood donation and safety standards. As the need for safe blood continues to grow across medical and surgical applications, the blood screening market is expected to remain a crucial component of global healthcare systems.
Tariff Impact Analysis for Blood Screening Market:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Blood Screening Market Overview:
The blood screening market is witnessing steady growth driven by an increasing need for safe blood transfusion, rising prevalence of infectious diseases, and advancements in screening technologies. The growing emphasis on healthcare safety protocols across both developed and developing nations further strengthens market expansion.
Market Trend:
A key trend driving the Blood Screening Market is the growing adoption of nucleic acid testing (NAT), which offers higher sensitivity and faster detection of bloodborne pathogens. Automation and integration of advanced technologies in screening platforms are also on the rise, helping laboratories improve accuracy and throughput. Moreover, the trend of decentralized testing in blood banks and community healthcare centers is gaining popularity, making screening more accessible and efficient.
Market Segmentation:
The blood screening market is broadly segmented based on technology, product type, and end-users. In terms of technology, the market includes nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and rapid testing methods. NAT is gaining significant traction due to its high sensitivity in detecting viral pathogens early in the infection cycle. ELISA remains widely used for routine screenings because of its reliability and cost-effectiveness, while CLIA offers enhanced automation and precision. On the basis of product type, the market is divided into reagents and kits, instruments, and software and services. Reagents and kits account for a large portion of the market, as they are essential for conducting accurate tests, while instruments and software play a supporting role in test execution and data analysis. Regarding end-users, the blood screening market serves blood banks, hospitals, and diagnostic laboratories. Blood banks represent a major share due to the constant demand for safe blood supplies, whereas hospitals and labs utilize screening technologies for pre-surgical assessments and routine diagnostics. This comprehensive segmentation highlights the diverse applications and users that drive the demand for blood screening solutions across the healthcare ecosystem.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Other Players
Market Growth:
The blood screening market is growing due to the increasing volume of blood donations and rising cases of transfusion-transmitted infections. Improved awareness among healthcare providers and patients about early detection of diseases like HIV, hepatitis, and syphilis contributes to this growth. Additionally, the introduction of automation and next-generation screening platforms in laboratories has enhanced the efficiency and accuracy of screening procedures, supporting continued market expansion.
Restraining Factors:
The blood screening market faces several restraining factors that could hinder its growth despite increasing demand for safe blood. One of the primary challenges is the high cost associated with advanced screening technologies such as nucleic acid testing and chemiluminescence assays. These methods, while highly effective, require significant investment in equipment, reagents, and skilled personnel, making them less accessible in low-resource settings. Additionally, many developing regions lack the necessary healthcare infrastructure and laboratory capacity to implement widespread screening programs effectively. Another major limitation is the regulatory complexity involved in introducing new screening methods, with varied and stringent compliance standards across countries slowing down product approvals and market entry. Furthermore, a shortage of trained professionals, particularly in rural and underdeveloped areas, can impact the accuracy and efficiency of blood screening procedures, ultimately affecting the quality of healthcare delivery.
Regional Analysis:
From a regional perspective, the blood screening market is showing distinct growth trends across different parts of the world. North America holds a leading position, driven by robust healthcare infrastructure, high awareness levels, and the presence of key industry players. The region benefits from widespread adoption of advanced screening technologies and a well-established system for blood donation and transfusion. Europe also contributes significantly to the market, supported by stringent regulatory frameworks and public health initiatives promoting blood safety. In contrast, the Asia-Pacific region is emerging as the fastest-growing market due to rising healthcare expenditures, increasing government support, and a growing focus on disease prevention through early detection. Countries like China and India are investing heavily in healthcare infrastructure, boosting the adoption of modern screening technologies. Meanwhile, Latin America and the Middle East & Africa are gradually advancing in the blood screening space, although progress is often slowed by limited resources and inadequate public health systems. Nonetheless, international health organizations and local governments are working to improve blood safety in these regions, which is expected to drive future growth.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com